Document Detail


Chronic venous insufficiency and the therapeutic effects of Daflon 500 mg.
MedLine Citation:
PMID:  16193222     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Chronic venous insufficiency is linked to venous hypertension and forces of shear stress on the endothelium. Venous hypertension depends upon two forces: the weight of a column of blood from the right atrium transmitted through the valveless vena cava and iliac veins to the femoral vein, and pressure generated by contracting skeletal muscles of the leg transmitted through failed perforating veins. When valve failure occurs in superficial axial veins and perforating veins, the venous pressure in the veins and venules of the skin and subcutaneous tissue is raised. The skin changes in chronic venous insufficiency are directly related to the severity of the venous hypertension. Also, pathologic changes in the valves are linked to venous hypertension and leukocyte infiltration and activation. It is hypothesized that acute venous pressure elevations cause a shift in the venous hemodynamics with changes in wall shear stress. This initiates the inflammatory cascade. Daflon 500 mg ameliorates the effects of chronic inflammation. In randomized trials, 60 days of therapy with Daflon at a dosage of 500 mg 2 tablets daily was effective, in addition to elastic compression, in accelerating venous ulcer healing. Because venous insufficiency is linked to venous hypertension and an inflammatory reaction, it appears that Daflon 500 mg 2 tablets daily shows a great potential for accomplishing blockade of the inflammatory cascade.
Authors:
John J Bergan
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Angiology     Volume:  56 Suppl 1     ISSN:  0003-3197     ISO Abbreviation:  Angiology     Publication Date:    2005 Sep-Oct
Date Detail:
Created Date:  2005-09-29     Completed Date:  2005-11-14     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0203706     Medline TA:  Angiology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S21-4     Citation Subset:  IM    
Affiliation:
University of California, San Diego, CA, USA. jbergan@ucsd.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Chronic Disease
Clinical Trials as Topic
Diosmin / administration & dosage,  therapeutic use*
Humans
Hypertension / complications*,  immunology*,  physiopathology
Inflammation / drug therapy
Varicose Ulcer / drug therapy,  etiology
Venous Insufficiency / drug therapy*,  immunology*,  physiopathology
Wound Healing
Chemical
Reg. No./Substance:
520-27-4/Diosmin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Chronic venous disease and the leukocyte-endothelium interaction: from symptoms to ulceration.
Next Document:  Daflon 500 mg: symptoms and edema clinical update.